Blastic Plasmacytoid Dendritic Cell Neoplasm clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of relapsed/refractory BPDCN patients.